Group 1 - The core viewpoint of the article highlights the significant stock increase of JingTai Holdings (02228) by over 6% following the announcement of a collaboration with South Korea's Dong-A ST to develop innovative therapies for immune and inflammatory diseases using AI and robotics [1] - JingTai Technology anticipates a substantial increase in comprehensive revenue for the first half of the year, expecting no less than 500 million RMB, representing an annual increase of approximately 387% [1] - The company expects to turn a profit with a net income of no less than 50 million RMB, marking its first half-year profitability [1] Group 2 - The collaboration will leverage JingTai's AI and robotics-driven drug development platform to identify targets and design first-in-class or best-in-class drug candidates [1] - The financial performance improvement is primarily attributed to the partnership with DoveTree, which has significantly contributed to revenue growth through AI-based drug discovery solutions [1]

Core Viewpoint - Jingtai Holdings (02228) has seen a significant stock price increase of over 14%, currently trading at 9.3 HKD with a transaction volume of 2.226 billion HKD, following the announcement of a positive earnings forecast for the first half of the year [1] Financial Performance - The company anticipates a consolidated revenue of no less than 500 million RMB for the first half of the year, representing an annual increase of at least approximately 387% [1] - Jingtai Holdings expects to turn a profit with a net income of no less than 50 million RMB, marking the company's first half-year profitability [1] Strategic Partnership - The financial performance improvement is primarily attributed to the collaboration with DoveTree, where Jingtai provides drug discovery solutions and services based on its end-to-end AI drug discovery platform and integrated "AI + robotics" technology [1] - In June, Jingtai announced a strategic partnership with the US biopharmaceutical company DoveTree to develop candidate drugs in oncology and immune inflammation using its AI + robotics platform [1] Financial Terms of the Partnership - Jingtai received an upfront payment of 51 million USD from DoveTree on August 5, with potential subsequent payments of 49 million USD and milestone payments up to 5.89 billion USD [1] - DoveTree has obtained exclusive global commercialization rights for the developed drugs [1]

消息面上，晶泰控股近日发盈喜，预期截至2025年中期期间的集团综合收益将不少于人民币5亿元，同 比增加至少约387%；纯利不少于人民币5000万元；经调整纯利不少于人民币1.2亿元。这是集团首次实 现半年盈利。财务预期改善主要由于集团与DoveTree Medicines LLC及其联属公司合作，集团基于端到 端人工智能药物发现平台及综合"AI+机器人"技术，向DoveTree提供药物发现解决方案及服务，该合作 带动重大收益增长。集团收到首付款5100万美元，首付款已确认为集团于2025年中期期间的收益，并为 集团于报告期间的收益作出重大贡献。 东吴证券近期指出，公司为全球AI for Science稀缺标的，此次合作对于公司是里程碑事件，首付款金额 高于预期，证明了晶泰控股的人工智能+机器人技术在药物发现领域的价值，同时其商业模式已初具雏 形，为未来商业化订单落地打下坚实基础，未来中短期收入有望迎来快速增长；同时公司合作客户涵盖 新材料、能源、化工等领域公司，进一步打开公司成长天花板，建议重点关注。 晶泰控股(02228)涨超10%，截至发稿，涨10.34%，报8.22港元，成交额21.12亿港元。 ...

Core Viewpoint - JingTai Holdings (02228) has seen a significant stock increase of over 8%, currently trading at 8.06 HKD, with a transaction volume of 819 million HKD. The company anticipates a substantial improvement in financial performance for the first half of 2025, projecting a consolidated revenue of no less than 500 million RMB, representing an increase of at least approximately 387% year-on-year. This marks the company's first half-year profit [1]. Financial Performance Expectations - The company expects to turn from a loss to a profit, with a projected net profit of no less than 50 million RMB for the first half of 2025. Adjusted net profit (non-IFRS measure) is expected to be no less than 120 million RMB [1]. - The anticipated financial improvement is primarily attributed to the collaboration with DoveTree Medicines LLC and its affiliates, leveraging an end-to-end AI drug discovery platform and comprehensive "AI + Robotics" technology [1]. Revenue Contributions - The collaboration with DoveTree has led to significant revenue growth, with the company receiving an initial payment of 51 million USD, which has been recognized as revenue for the first half of 2025 and is expected to make a substantial contribution to the company's earnings during the reporting period [1]. - According to the agreement with DoveTree, the company is entitled to receive further payments, which will be recognized as revenue in batches in the future [1].

Group 1 - The company, Crystal Tech Holdings, has issued a positive profit forecast, expecting a consolidated revenue of no less than RMB 500 million for the six months ending mid-2025, representing an increase of at least approximately 387% compared to the revenue of about RMB 103 million for the six months ending June 30, 2024 [1] - The company anticipates a turnaround from a net loss of RMB 1.238 billion for the six months ending June 30, 2024, to a net profit of no less than RMB 50 million for the mid-2025 period [1] - The company also expects to shift from an adjusted net loss (non-IFRS) of RMB 251 million for the six months ending June 30, 2024, to an adjusted net profit (non-IFRS) of no less than RMB 120 million for the mid-2025 period, marking the company's first half-year profit [1] Group 2 - The anticipated improvement in the company's financial performance for the mid-2025 period is primarily due to its collaboration with DoveTree Medicines LLC and its affiliates, leveraging an end-to-end AI drug discovery platform and comprehensive "AI + robotics" technology to provide drug discovery solutions and services [2] - The company has received an upfront payment of USD 51 million, which has been recognized as revenue for the mid-2025 period and is expected to make a significant contribution to the company's revenue during the reporting period [2] - According to the terms of the agreement with DoveTree, the company is entitled to receive further payments, which will be recognized as revenue in future installments [2]

Group 1 - The company expects a significant increase in consolidated revenue for the period ending mid-2025, projecting at least RMB 500 million, which represents an increase of at least approximately 387% compared to the revenue of about RMB 103 million for the six months ending June 30, 2024 [1] - The company anticipates a turnaround from a net loss of RMB 1.238 billion for the six months ending June 30, 2024, to a net profit of no less than RMB 50 million for the mid-2025 period [1] - The company also expects to shift from an adjusted net loss (non-IFRS) of RMB 251 million for the six months ending June 30, 2024, to an adjusted net profit (non-IFRS) of at least RMB 120 million for the mid-2025 period, marking the company's first half-year profit [1] Group 2 - The anticipated improvement in financial performance for the mid-2025 period is primarily due to the collaboration with DoveTree Medicines LLC and its affiliates, leveraging an end-to-end AI drug discovery platform and comprehensive "AI + robotics" technology [2] - The company received an upfront payment of USD 51 million, which has been recognized as revenue for the mid-2025 period and significantly contributes to the company's earnings during the reporting period [2] - According to the agreement terms with DoveTree, the company is entitled to receive further payments, which will be recognized as revenue in batches in the future [2]

Core Viewpoint - The company anticipates significant financial improvement for the six months ending June 30, 2025, with a projected comprehensive income of at least RMB 500 million, marking an increase of at least 387% compared to RMB 103 million for the same period in 2024 [1][2] Financial Performance Expectations - The company expects to turn a loss into profit, with a projected net profit of at least RMB 50 million for the six months ending June 30, 2025, compared to a net loss of RMB 1.238 billion for the same period in 2024 [1] - The adjusted net loss (non-IFRS) for the six months ending June 30, 2024, was RMB 251 million, which is expected to turn into an adjusted net profit (non-IFRS) of at least RMB 120 million for the 2025 mid-term period [1] Revenue Growth Drivers - The anticipated financial improvement is primarily attributed to the collaboration with DoveTree Medicines LLC and its affiliates, leveraging an end-to-end AI drug discovery platform and comprehensive "AI + Robotics" technology [2] - The company received an upfront payment of USD 51 million, which has been recognized as revenue for the six months ending June 30, 2025, significantly contributing to the expected revenue growth [2] - Further payments are expected under the agreement with DoveTree, which will be recognized as revenue in future installments [2]